Frovatriptan well tolerated when used as six-day
      dosing regimen for up to six menstrual periods as preventive therapy
                        for Menstrually Related Migraine

Vernalis plc (LSE: VER, NASDAQ: VNLS) today announced six-month interim safety
data for frovatriptan, in development for the prevention of menstrually related
migraine (MRM) and marketed as Frova(R) in the U.S. by Vernalis' partner, Endo
Pharmaceuticals Inc. The data were presented at the 47th Annual Scientific
Meeting of the American Headache Society which took place in Philadelphia June
23-26, 2005.

The interim data seem to indicate that frovatriptan is well-tolerated when used
as a six-day dosing regimen for up to six menstrual periods as preventive
therapy for MRM. No serious adverse events attributed to frovatriptan were
reported. The trial is now nearing completion, with currently more than 300
patients having received 12 months of treatment. This exceeds the study
objective of treating 100 patients for 12 menstrual cycles.

Migraine expert Dr Anne MacGregor commented, 'This is a promising set of results
in this population with MRM.  Many women are disabled by menstrual attacks of
migraine, which are often more severe and less responsive to existing treatments
than attacks at other times of the cycle. Hence there is a real need for
well-tolerated, effective and specific prophylactic treatments for this
condition.'

'Frovatriptan's distinctively long half-life of 26 hours is a key element in our
interest in determining whether it is an appropriate agent for migraine
prophylaxis,' said Simon Sturge, CEO of Vernalis. 'The interim safety data from
this study support our goal of seeking approval for frovatriptan for the
prevention of MRM.'

                                    - ends -

Notes to Editors

This safety trial is one of three required trials to complete the data package
for a supplemental New Drug Approval (sNDA) application to market frovatriptan
as a short-term prophylaxis for MRM in the U.S. The first, a 500-patient
efficacy study, was completed in April 2003 and was reported in the journal
Neurology in July 2004. The remaining two trials, the safety study and the
second efficacy study, are ongoing, with regulatory submission expected in the
first-half of 2006.

   • MRM Phase III Efficacy Study

In October 2002, positive trial data were first presented from a study of more
than 500 menstrual migraine sufferers in the U.S., suggesting that short-term
prophylaxis with frovatriptan was effective in preventing migraine headaches
triggered by menstruation. The data demonstrated a highly statistically
significant improvement in the numbers of patients who were headache-free during
their menstrual cycles for both once and twice daily dose regimens of
frovatriptan compared to placebo (p < 0.0001). These data were published in full
by a leading journal, Neurology (2004, 63: 261-269).

   • MRM Phase III Safety Study

The 12 month, safety study, now fully enrolled, investigated the higher dose
regimen that showed positive signs of efficacy in the initial efficacy study
that was published in Neurology in July 2004. In this safety study, female
patients take frovatriptan tablets for six days each month (2 x 2.5 mg twice
daily on day 1, and 2.5 mg twice daily for five days) covering their menstrual
cycles. The pre-specified safety review was planned to occur once 300 patients
had completed treatment for six menstrual cycles.
The analysis was conducted on data from 442 patients, of whom 313 had complete
data from at least six menstrual cycles. Any patient who had taken at least one
dose of frovatriptan was included in the safety analysis. The mean age of
patients was 37.5 years and the average duration of MRMs was 11 years. The
average number of MRMs experienced by patients in the previous year was 11.3. A
majority of the patients (83%) had experienced their migraines on the day of
menstruation or up to two days beforehand, as previously reported.

The trial is now nearing completion, with currently more than 300 patients
having received 12 months of treatment. This exceeds the study objective of
treating 100 patients for 12 menstrual cycles.

   • Second MRM Phase III Efficacy Study

A second, placebo-controlled, parallel group efficacy study began recruitment in
October 2004 and is investigating the same dose regimen that was efficacious in
the initial study, published in Neurology in July 2004. Female patients take
frovatriptan tablets for six days each month covering their menstrual cycle.
Around 600 patients whose menstrually related migraines are difficult to treat
using acute therapies are being enrolled and treated for three consecutive
months.

About Frova(R)

Frova(R) was approved by the FDA on November 8, 2001 for the acute treatment of
migraine attacks with or without aura (subjective symptoms at the onset of a
migraine headache) in adults. Frova(R) is generally well tolerated, with a
side-effect profile that is typical of the triptan class of drugs. Frova(R) is
indicated for the acute treatment of migraine attacks with or without aura in
adults where a clear diagnosis of migraine has been established. Frova(R) is not
intended for the prophylactic therapy of migraine or for use in the management
of hemiplegic or basilar migraine. The safety and effectiveness of Frova(R) have
not been established for cluster headache, which is present in an older,
predominantly male population.

Frova(R) should not be given to patients with cerebrovascular syndromes,
peripheral vascular disease, uncontrolled hypertension, ischemic heart disease,
or to patients who have symptoms or findings consistent with ischemic heart
disease, coronary artery vasospasm, including Prinzmetal's variant angina or
other significant underlying cardiovascular disease. Frova(R) should not be
given to patients within whom unrecognized coronary artery disease is predicted
by the presence of risk factors without a prior cardiovascular evaluation.
The most common adverse events (4%) include dizziness, fatigue, paresthesia,
flushing, and headache.

The FDA-approved dosing for Frova(R) is one 2.5 mg tablet up to three times
within a 24-hour period. Frova(R) has not been approved by the FDA for any
indications other than for the treatment of acute migraine headaches, and its
safety and efficacy in other indications have not been established.
Frova(R) is licensed for this indication in the US. For other countries, check
local prescribing information. Not necessarily licensed for this indication
outside the US. Not for release in the UK.